Fox Run Management’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
Fox Run Management's AMRX Position: Q1 2026 in Review
Fox Run Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 33,724 shares — an estimated $425K sold.
Fox Run Management first reported a position in AMRX in Q2 2018 and held it in 6 quarters. The position peaked at $425K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.
- Fox Run Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Fox Run Management sold 33,724 Amneal Pharmaceuticals shares in Q1 2026, an estimated $425K.
- Fox Run Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 6 quarters.
- Fox Run Management's Amneal Pharmaceuticals position peaked at $425K in Q4 2025.
- 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.
Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.